An overview on medicinal chemistry of synthetic and natural derivatives of cannabidiol

Frontiers in Pharmacology

Volumn 8, Issue JUN, 2017, Pages

  Morales, Paula ^a   Reggio, Patricia H ^a   Jagerovic, Nadine ^b  

^a UNIVERSITY OF NORTH CAROLINA AT GREENSBORO   (United States)

^b INSTITUTO DE QUÍMICA MÉDICA   (Spain)

Author keywords

Cannabidiol; Cannabidiol derivative; Cannabinoid receptor; Molecular target; Therapeutic application

Indexed keywords

CANNABIDIOL DERIVATIVE; CANNABIDIOL METHYL ETHER; CANNABIDIOLIC ACID; CANNABIDIORCOL; CANNABIDIVARIN; CANNABIDIVARINIC ACID; CANNABIELSOIN; CANNABINODIOL; CANNABINODIVARIN; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; DIHYDROCANNABIDIOL; FERRUGINENE C; MACHAERIDIOL B; MOLECULAR SCAFFOLD; NEUROLEPTIC AGENT; NITRIC OXIDE; PHENOL; QUINONE DERIVATIVE; REACTIVE OXYGEN METABOLITE; RESORCINOL; SEROTONIN; TETRAHYDROCANNABIDIOL; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANTICONVULSANT THERAPY; ANTIINFLAMMATORY ACTIVITY; BINDING AFFINITY; CHEMICAL MODIFICATION; CROHN DISEASE; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG RECEPTOR BINDING; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TARGETING; HALOGENATION; HUMAN; LENNOX GASTAUT SYNDROME; MEDICINAL CHEMISTRY; MIGRATION INHIBITION; NEUROPROTECTION; NONHUMAN; REVIEW; SEVERE MYOCLONIC EPILEPSY IN INFANCY; TRANQUILIZING ACTIVITY;

EID: 85021666610     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2017.00422     Document Type: Review

References (135)

1. Ahrens, J., Demir, R., Leuwer, M., De La Roche, J., Krampfl, K., Foadi, N., et al. (2009). The nonpsychotropic cannabinoid cannabidiol modulates and directly activates alpha-1 and alpha-1-beta glycine receptor function. Pharmacology 83, 217-222. doi: 10.1159/000201556
2. Aizpurua-Olaizola, O., Soydaner, U., öztürk, E., Schibano, D., Simsir, Y., Navarro, P., et al. (2016). Evolution of the cannabinoid and terpene content during the growth of cannabis sativa plants from different chemotypes. J. Nat. Prod. 79, 324-331. doi: 10.1021/acs.jnatprod.5b00949
3. Anavi-Goffer, S., Baillie, G., Irving, A. J., Gertsch, J., Greig, I. R., Pertwee, R. G., et al. (2012). Modulation of L-a-lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids. J. Biol. Chem. 287, 91-104. doi: 10.1074/jbc. M111.296020
4. Appendino, G., Cabello de Alba, M. L. B., and Munoz Blanco, E. (2015). Preparation of novel cannabidiol quinone derivatives as PPARγ agonists. International Patent No WO2015/158381. Washington, DC
5. Appendino, G., Gibbons, S., Giana, A., Pagani, A., Grassi, G., Stavri, M., et al. (2008). Antibacterial Cannabinoids from Cannabis sativa: a structure-activity study. J. Nat. Prod. 71, 1427-1430. doi: 10.1021/np8002673
6. Ashton, J. C. (2012). The atypical cannabinoid O-1602: targets, actions, and the central nervous system. Cent. Nerv. Syst. Agents Med. Chem. 12, 233-239. doi: 10.2174/187152412802430156
7. Bakas, T., Devenish, S., Van Nieuwenhuizen, P., Arnold, J., McGregor, I., and Collins, M. (2016). "The actions of cannabidiol and 2-arachidonyl glicerol on GABA-A receptors". in Proceedings of the 26th Annual Symposium on the Cannabinoids, International Cannabinoid Research Society, Bukovina, 28
8. Ben-Shabat, S., Hanuš, L. O., Katzavian, G., and Gallily, R. (2006). New cannabidiol derivatives: synthesis, binding to cannabinoid receptor, and evaluation of their antiinflammatory activity. J. Med. Chem. 49, 1113-1117. doi: 10.1021/jm050709m
9. Berber, H., Lameiras, P., Denhez, C., Antheaume, C., and Clayden, J. (2014). Atropisomerism about aryl-csp3 bonds: the electronic and steric influence of ortho-substituents on conformational exchange in cannabidiol and linderatin derivatives. J. Org. Chem. 79, 6015-6027. doi: 10.1021/jo5006069
10. Bhattacharyya, S., Morrison, P. D., Fusar-Poli, P., Martin-Santos, R., Borgwardt, S., Winton-Brown, T., et al. (2010). Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 35, 764-774. doi: 10.1038/npp.2009.184
11. Bisogno, T., Hanus, L., De Petrocellis, L., Tchilibon, S., Ponde, D. E., Brandi, I., et al. (2001). Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br. J. Pharmacol. 134, 845-852. doi: 10.1038/sj.bjp.0704327
12. Bornheim, L. M., and Grillo, M. P. (1998). Characterization of cytochrome P450 3A inactivation by cannabidiol-hydrozyquinone as a P450 inactivator. Chem. Res. Toxicol. 11, 1209-1216. doi: 10.1021/tx9800598
13. Borrelli, F., Fasolino, I., Romano, B., Capasso, R., Maiello, F., Coppola, D., et al. (2013). Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochem. Pharmacol. 85, 1306-1316. doi: 10.1016/j.bcp.2013.01.017
14. Breuer, A., Haj, C. G., Fogaça, M. V., Gomes, F. V., Silva, N. R., Pedrazzi, J. F., et al. (2016). Fluorinated cannabidiol derivatives: enhancement of activity in mice models predictive of anxiolytic, antidepressant and antipsychotic effects. PLoS ONE 11:e0158779. doi: 10.1371/journal.pone.0158779
15. Burstein, S. (2015). Cannabidiol (CBD) and its analogs: a review of their effects on inflammation. Bioorgan. Med. Chem. 23, 1377-1385. doi: 10.1016/j.bmc.2015.01.059
16. Carlini, E. A., Mechoulam, R., and Lander, N. (1975). Anticonvulsant activity of four oxygenated cannabidiol derivatives. Res. Commun. Chem. Pathol. Pharmacol. 12, 1-15
17. Carreras, J., Kirillova, M. S., and Echavarren, A. M. (2016). Synthesis of (-)-cannabimovone and structural reassignment of anhydrocannabimovone through gold(I)-catalyzed cycloisomerization. Angew. Chemie-Int. Ed. 55, 7121-7125. doi: 10.1002/anie.201601834
18. Cascio, M. G., Gauson, L. A., Stevenson, L. A., Ross, R. A., and Pertwee, R. G. (2010). Evidence that the plant cannabinoid cannabigerol is a highly potent a 2-adrenoceptor agonist and moderately potent 5HT 1A receptor antagonist. Br. J. Pharmacol. 159, 129-141. doi: 10.1111/j.1476-5381.2009.00515.x
19. Clayden, J., Moran, W. J., Edwards, P. J., and Laplante, S. R. (2009). The challenge of atropisomerism in drug discovery. Angew. Chemie-Int. Ed. 48, 6398-6401. doi: 10.1002/anie.200901719
20. Console-Bram, L., Brailoiu, E., Brailoiu, G. C., Sharir, H., and Abood, M. E. (2014). Activation of GPR18 by cannabinoid compounds: a tale of biased agonism. Br. J. Pharmacol. 171, 3908-3917. doi: 10.1111/bph.12746
21. De Petrocellis, L., Ligresti, A., Moriello, A. S., Allarà, M., Bisogno, T., Petrosino, S., et al. (2011). Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br. J. Pharmacol. 163, 1479-1494. doi: 10.1111/bph.2011.163.issue-7
22. De Petrocellis, L., Orlando, P., Moriello, A. S., Aviello, G., Stott, C., Izzo, A. A., et al. (2012). Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation. Acta Physiol. 204, 255-266. doi: 10.1111/j.1748-1716.2011.02338.x
23. Devinsky, O., Marsh, E., Friedman, D., Thiele, E., Laux, L., Sullivan, J., et al. (2015). Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 15, 270-278. doi: 10.1016/S1474-4422(15)00379-8
24. El-Alfy, A. T., Ivey, K., Robinson, K., Safwat, A., Radwan, M., Slade, D., et al. (2010). Antidepressant-like effect of 9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L. Pharmacol. Biochem. Behav. 95, 434-442. doi: 10.1016/j.pestbp.2011.02.012.Investigations
25. Elmes, M. W., Kaczocha, M., Berger, W. T., Leung, K., Ralph, B. P., Wang, L., et al. (2015). Fatty acid-binding proteins (FABPs) are intracellular carriers for 9-tetrahydrocannabinol (THC) and cannabidiol (CBD). J. Biol. Chem. 290, 8711-8721. doi: 10.1074/jbc. M114.618447
26. ElSohly, M. A., and Gul, W. (2014). "Constituents of cannabis sativa". in Handbook of Cannabis, ed. R. G. Pertwee (Oxford: Oxford University Press), 3-22. doi: 10.1093/acprof
27. ElSohly, M. A., and Slade, D. (2005). Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci. 78, 539-548. doi: 10.1016/j.lfs.2005.09.011
28. Esposito, G., Scuderi, C., Valenza, M., Togna, G. I., Latina, V., de Filippis, D., et al. (2011). Cannabidiol reduces Aβ-induced neuroinflammation and promotes hippocampal neurogenesis through PPARγ involvement. PLoS ONE 6:e28668. doi: 10.1371/journal.pone.0028668
29. Fasinu, P. S., Phillips, S., Elsohly, M. A., and Walker, L. A. (2016). Current status and prospects for cannabidiol preparations as new therapeutic agents. Pharmacotherapy 36, 781-796. doi: 10.1111/j.1875-9114.2016.01780.x
30. Fernandez, O. (2016). THC:CBD in daily practice: available data from UK, germany and spain. Eur. Neurol. 75, 1-3. doi: 10.1159/000444234
31. Fernandez-Ruiz, J., Sagredo, O., Pazos, M. R., Garcia, C., Pertwee, R., Mechoulam, R., et al. (2013). Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? Br. J. Clin. Pharmacol. 75, 323-333. doi: 10.1111/j.1365-2125.2012.04341.x
32. Flos, M., Lameiras, P., Denhez, C., Mirand, C., and Berber, H. (2016). Atropisomerism about Aryl-C(sp3) Bonds: conformational behavior of substituted phenylcyclohexanes in solution. J. Org. Chem. 81, 2372-2382. doi: 10.1021/acs.joc.5b02856
33. Ford, L. A., Roelofs, A. J., Anavi-Goffer, S., Mowat, L., Simpson, D. G., Irving, A. J., et al. (2010). A role for L-alpha-lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells. Br. J. Pharmacol. 160, 762-771. doi: 10.1111/j.1476-5381.2010.00743.x
34. Fride, E., Feigin, C., Ponde, D. E., Breuer, A., Hanuš, L., Arshavsky, N., et al. (2004). (+)-Cannabidiol analogues which bind cannabinoid receptors but exert peripheral activity only. Eur. J. Pharmacol. 506, 179-188. doi: 10.1016/j.ejphar.2004.10.049
35. Fride, E., Ponde, D., Breuer, A., and Hanuš, L. (2005). Peripheral, but not central effects of cannabidiol derivatives: mediation by CB1 and unidentified receptors. Neuropharmacology 48, 1117-1129. doi: 10.1016/j.neuropharm.2005.01.023
36. Gaoni, Y., and Mechoulam, R. (1971). The isolation and structure of delta-1-tetrahydrocannabinol and other neutral cannabinoids from hashish. J. Am. Chem. Soc. 93, 217-224. doi: 10.1021/ja00730a036
37. Gertsch, J., Pertwee, R. G., and Di Marzo, V. (2010). Phytocannabinoids beyond the cannabis plant-do they exist? Br. J. Pharmacol. 160, 523-529. doi: 10.1111/j.1476-5381.2010.00745.x
38. Gonca, E., and Darici, F. (2014). The effect of cannabidiol on ischemia/reperfusion-induced ventricular arrhythmias: the role of adenosine A1 receptors. J. Cardiovasc. Pharmacol. Ther. 1:76. doi: 10.1177/1074248414532013
39. Haj, C. G., Sumariwalla, P. F., Hanuš, L., Kogan, N. M., Yektin, Z., Mechoulam, R., et al. (2015). HU-444, a novel, potent anti-inflammatory, nonpsychotropic cannabinoid. J. Pharmacol. Exp. Ther. 355, 66-75. doi: 10.1124/jpet.115.226100
40. Hanus, L., Breuer, A., Tchilibon, S., Shiloah, S., Goldenberg, D., Horowitz, M., et al. (1999). HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc. Natl. Acad. Sci. U.S.A. 96, 14228-14233. doi: 10.1073/pnas.96.25.14228
41. Hanuš, L. O., Meyer, S. M., Muñoz, E., Taglialatela-Scafati, O., and Appendino, G. (2016). Phytocannabinoids: a unified critical inventory. Nat. Prod. Rep. 33, 1357-1392. doi: 10.1039/c6np00074f
42. Hanus, L. O., Tchilibon, S., Ponde, D. E., Breuer, A., Fride, E., and Mechoulam, R. (2005). Enantiomeric cannabidiol derivatives: synthesis and binding to cannabinoid receptors. Org. Biomol. Chem. 3, 1116-1123. doi: 10.1039/b416943c
43. Hartsel, S. C., Loh, W. H., and Robertson, L. W. (1983). Biotransformation of cannabidiol to cannabielsoin by suspension cultures of Cannabis sativa and Saccharum officinarum. Planta Med. 48, 17-19. doi: 10.1055/s-2007-969870
44. Hendricks, H., Malingré, T. M., Batterman, S., and Bos, R. (1978). The essential oil of Cannabis sativa. Pharm. Weekbl. 113, 413-424
45. Hill, A. J., Mercier, M. S., Hill, T. D. M., Glyn, S. E., Jones, N. A., Yamasaki, Y., et al. (2012). Cannabidivarin is anticonvulsant in mouse and rat. Br. J. Pharmacol. 167, 1629-1642. doi: 10.1111/j.1476-5381.2012.02207.x
46. Hill, T. D. M., Cascio, M. G., Romano, B., Duncan, M., Pertwee, R. G., Williams, C. M., et al. (2013). Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism. Br. J. Pharmacol. 170, 679-692. doi: 10.1111/bph.12321
47. Huang, Q., Wang, Q., Zheng, J., Zhang, J., Pan, X., and She, X. (2007). A general route to 5, 6-seco-hexahydrodibenzopyrans and analogues: first total synthesis of (+)-Machaeridiol B and (+)-Machaeriol B. Tetrahedron 63, 1014-1021. doi: 10.1016/j.tet.2006.10.067
48. Ibeas Bih, C., Chen, T., Nunn, A. V. W., Bazelot, M., Dallas, M., and Whalley, B. J. (2015). Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics 12, 699-730. doi: 10.1007/s13311-015-0377-3
49. Johns, D. G., Behm, D. J., Walker, D. J., Ao, Z., Shapland, E. M., Daniels, D. A., et al. (2007). The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br. J. Pharmacol. 152, 825-831. doi: 10.1038/sj.bjp.0707419
50. Jones, N. A., and Whalley, B. J. (2015). Progress report on new antiepileptic drugs: a summary of the Twelfth Eilat Conference (EILAT XII). Epilepsy Res. 111, 113-114. doi: 10.1016/j.eplepsyres.2015.01.001
51. Juknat, A., Kozela, E., Kaushansky, N., Mechoulam, R., and Vogel, Z. (2016). Anti-inflammatory effects of the cannabidiol derivative dimethylheptyl-cannabidiol-studies in BV-2 microglia and encephalitogenic T cells. J. Basic Clin. Physiol. Pharmacol. 27, 289-296. doi: 10.1515/jbcpp-2015-0071
52. Kinney, W. A., McDonnell, M. E., Zhong, H. M., Liu, C., Yang, L., Ling, W., et al. (2016). Discovery of KLS-13019, a cannabidiol-derived neuroprotective agent, with improved potency, safety, and permeability. ACS Med. Chem. Lett. 7, 424-428. doi: 10.1021/acsmedchemlett.6b00009
53. Kogan, N. M., Rabinowitz, R., Levi, P., Gibson, D., Sandor, P., Schlesinger, M., et al. (2004). Synthesis and antitumor activity of quinonoid derivatives of cannabinoids. J. Med. Chem. 47, 3800-3806. doi: 10.1021/jm040042o
54. Kogan, N. M., Schlesinger, M., Priel, E., Rabinowitz, R., Berenshtein, E., Chevion, M., et al. (2007). HU-331, a novel cannabinoid-based anticancer topoisomerase II inhibitor. Mol. Cancer Ther. 6, 173-183. doi: 10.1158/1535-7163.MCT-06-0039
55. Kozela, E., Haj, C., Hanuš, L., Chourasia, M., Shurki, A., Juknat, A., et al. (2015). HU-446 and HU-465, derivatives of the non-psychoactive cannabinoid cannabidiol, decrease the activation of encephalitogenic T cells. Chem. Biol. Drug Des. 87, 143-153. doi: 10.1111/cbdd.12637
56. Krohn, R. M., Parsons, S. A., Fichna, J., Patel, K. D., Yates, R. M., Sharkey, K. A., et al. (2016). Abnormal cannabidiol attenuates experimental colitis in mice, promotes wound healing and inhibits neutrophil recruitment. J. Inflamm. 13:21. doi: 10.1186/s12950-016-0129-0
57. Lafuente, H., Alvarez, F. J., Pazos, M. R., Alvarez, A., Rey-Santano, M. C., Mielgo, V., et al. (2011). Cannabidiol reduces brain damage and improves functional recovery after acute hypoxia-ischemia in newborn pigs. Pediatr. Res 70, 272-277. doi: 10.1203/PDR.0b013e3182276b11
58. Laprairie, R. B., Bagher, A. M., Kelly, M. E. M., and Denovan-Wright, E. M. (2015). Cannabidiol is a negative allosteric modulator of the type 1 cannabinoid receptor. Br. J. Pharmacol. 172, 4790-4805. doi: 10.1111/bph.13250
59. Lauckner, J. E., Jensen, J. B., Chen, H.-Y., Lu, H.-C., Hille, B., and Mackie, K. (2008). GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc. Natl. Acad. Sci. U.S.A. 105, 2699-2704. doi: 10.1073/pnas.0711278105
60. Leite, J. R., Carlini, E. A., Lander, N., and Mechoulam, R. (1982). Anticonvulsant effects of the (-) and (+)isomers of cannabidiol and their dimethylheptyl homologs. Pharmacology 24, 141-146. doi: 10.1159/000137588
61. Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., et al. (2012). Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl. Psychiatry 2:e94. doi: 10.1038/tp.2012.15
62. Li, K., Feng, J., Li, Y., Yuece, B., Lin, X., Yu, L., et al. (2013). Anti-inflammatory role of cannabidiol and O-1602 in cerulein-induced acute pancreatitis in mice. Pancreas 42, 123-129. doi: 10.1097/MPA.0b013e318259f6f0
63. Ligresti, A. (2006). Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J. Pharmacol. Exp. Ther. 318, 1375-1387. doi: 10.1124/jpet.106.105247
64. Maione, S., Piscitelli, F., Gatta, L., Vita, D., De Petrocellis, L., Palazzo, E., et al. (2011). Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action. Br. J. Pharmacol. 162, 584-596. doi: 10.1111/j.1476-5381.2010.01063.x
65. Massi, P., Solinas, M., Cinquina, V., and Parolaro, D. (2013). Cannabidiol as potential anticancer drug. Br. J. Clin. Pharmacol. 75, 303-312. doi: 10.1111/j.1365-2125.2012.04298.x
66. Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., and Bonner, T. I. (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561-564. doi: 10.1038/346561a0
67. McAllister, S. D., Murase, R., Christian, R. T., Lau, D., Zielinski, A. J., Allison, J., et al. (2011). Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. Breast Cancer Res. Treat. 129, 37-47. doi: 10.1007/s10549-010-1177-4
68. McHugh, D., Page, J., Dunn, E., and Bradshaw, H. B. (2012). 9-Tetrahydrocannabinol and N-arachidonyl glycine are full agonists at GPR18 receptors and induce migration in human endometrial HEC-1B cells. Br. J. Pharmacol. 165, 2414-2424. doi: 10.1111/j.1476-5381.2011.01497.x
69. McHugh, D., Roskowski, D., Xie, S., and Bradshaw, H. B. (2014). 9-THC and N-arachidonoyl glycine regulate BV-2 microglial morphology and cytokine release plasticity: implications for signaling at GPR18. Front. Pharmacol. 4:162. doi: 10.3389/fphar.2013.00162
70. McKillop, A. M., Moran, B. M., Abdel-Wahab, Y. H. A., Gormley, N. M., and Flatt, P. R. (2016). Metabolic effects of orally administered small-molecule agonists of GPR55 and GPR119 in multiple low-dose streptozotocin-induced diabetic and incretin-receptor-knockout mice. Diabetologia 59, 2674-2685. doi: 10.1007/s00125-016-4108-z
71. McPartland, J. M., Glass, M., and Pertwee, R. G. (2007). Meta-analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences. Br. J. Pharmacol. 152, 583-593. doi: 10.1038/sj.bjp.0707399
72. Mechoulam, R., Ben-Zvi, Z., and Gaoni, Y. (1968). Hashish-XIII. On the nature of the beam test. Tetrahedron 24, 5615-5624. doi: 10.1016/0040-4020(68)88159-1
73. Mechoulam, R., Feigenbaum, J. J., Lander, N., Segal, M., Hiltunen, T. U. C., and Consroe, P. (1988). Enantiomeric cannabinoids: stereospecificity of psychotropic activity. Experientia 44, 762-764. doi: 10.1007/BF01959156
74. Mechoulam, R., and Hanuš, L. (2002). Cannabidiol: an overview of some chemical and pharmacological aspects, Part I: Chemical aspects. Chem. Phys. Lipids 121, 35-43. doi: 10.1016/S0009-3084(02)00144-5
75. Mechoulam, R., Hanuš, L. O., Pertwee, R., and Howlett, A. C. (2014). Early phytocannabinoid chemistry to endocannabinoids and beyond. Nat. Rev. Neurosci. 15, 757-764. doi: 10.1038/nrn3811
76. Mechoulam, R., Kogan, N. M., Gallily, R., and Breuer, A. (2008). Novel Cannabidiol Derivatives and their use as anti-inflammatory agents. ternational Patent No WO2008/107879. Washington, DC
77. Mechoulam, R., Lander, N., Breuer, A., and Zahalka, J. (1990). Synthesis of the individual, pharmacologically distinct enantiomers of a tetrahydrocannabinol derivative. Tetrahedron Asymmetry 1, 315-318. doi: 10.1016/S0957-4166(00)86322-3
78. Mechoulam, R., Peters, M., Murillo-Rodriguez, E., and Hanus, L. O. (2007). Cannabidiol-recent advances. Chem. Biodivers. 4, 1678-1692. doi: 10.1002/cbdv.200790147
79. Morales, P., Goya, P., Jagerovic, N., and Hernandez-Folgado, L. (2016). Allosteric modulators of the CB1 cannabinoid receptor: a structural update review. Cannabis Cannabinoid Res. 1, 22-30. doi: 10.1089/can.2015.0005
80. Morales, P., Hurst, D. P., and Reggio, P. H. (2017). "Molecular targets of the phytocannabinoids: a complex picture". in Progress in the Chemistry of Organic Natural Products: Phytocannabinoids, Unravelling the Complex Chemistry and Pharmacology of Cannabis sativa, eds A. D. Kinghorn, H. Falk, S. Gibbons, and J. Kobayashi (Berlin: Springer), doi: 10.1007/978-3-319-45541-9_4
81. Mori, M. A., Meyer, E., Soares, L. M., Milani, H., Guimarães, F. S., and de Oliveira, R. M. W. (2017). Cannabidiol reduces neuroinflammation and promotes neuroplasticity and functional recovery after brain ischemia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 75, 94-105. doi: 10.1016/j.pnpbp.2016.11.005
82. Muhammad, I., Li, X.-C., Jacob, M. R., Tekwani, B. L., Dunbar, D. C., and Ferreira, D. (2003). Antimicrobial and antiparasitic (+)-trans-hexahydrodibenzopyrans and analogues from Machaerium multiflorum. J. Nat. Prod. 66, 804-809. doi: 10.1021/np030045o
83. Munro, S., Thomas, K. L., and Abu-Shaar, M. (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature 365, 61-65. doi: 10.1038/365061a0
84. Naftali, T., Mechulam, R., Marii, A., Gabay, G., Stein, A., Bronshtain, M., et al. (2017). Low-dose cannabidiol is safe but not effective in the treatment for Crohn's disease, a randomized controlled trial. Dig. Dis. Sci. 62, 1-6. doi: 10.1007/s10620-017-4540-z
85. Ofek, O., Karsak, M., Leclerc, N., Fogel, M., Frenkel, B., Wright, K., et al. (2006). Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc. Natl. Aacd. Sci. U.S.A. 103, 696-701. doi: 10.1021/jm4005626
86. Oka, S., Nakajima, K., Yamashita, A., Kishimoto, S., and Sugiura, T. (2007). Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem. Biophys. Res. Commun. 362, 928-934. doi: 10.1016/j.bbrc.2007.08.078
87. O'Sullivan, S. E., Sun, Y., Bennett, A. J., Randall, M. D., and Kendall, D. A. (2009). Time-dependent vascular actions of cannabidiol in the rat aorta. Eur. J. Pharmacol. 612, 61-68. doi: 10.1016/j.ejphar.2009.03.010
88. Pertwee, R. G., Ross, R. A., Craib, S. J., and Thomas, A. (2002). (-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens. Eur. J. Pharmacol. 456, 99-106. doi: 10.1016/S0014-2999(02)02624-9
89. Pertwee, R. G., Thomas, A., Stevenson, L. A., Maor, Y., and Mechoulam, R. (2005). Evidence that (-)-7-hydroxy-4'-dimethylheptyl-cannabidiol activates a non-CB1, non-CB2, non-TRPV1 target in the mouse vas deferens. Neuropharmacology 48, 1139-1146. doi: 10.1016/j.neuropharm.2005.01.010
90. Peters, M., and Kogan, N. M. (2007). HU-331: a cannabinoid quinone, with uncommon cytotoxic properties and low toxicity. Expert Opin. Investig. Drugs 16, 1405-1413. doi: 10.1517/13543784.16.9.1405
91. Petronzi, C., Festa, M., Peduto, A., Castellano, M., Marinello, J., Massa, A., et al. (2013). Cyclohexa-2, 5-diene-1, 4-dione-based antiproliferative agents?: design, synthesis, and cytotoxic evaluation. J. Exp. Clin. Cancer Res. 32:24. doi: 10.1186/1756-9966-32-24
92. Pucci, M., Rapino, C., Di Francesco, A., Dainese, E., D'Addario, C., and Maccarrone, M. (2013). Epigenetic control of skin differentiation genes by phytocannabinoids. Br. J. Pharmacol. 170, 581-591. doi: 10.1111/bph.12309
93. Rajesh, M., Mukhopadhyay, P., Batkai, S., Hasko, G., Liaudet, L., Huffman, J. W., et al. (2007a). CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am. J. Physiol. Heart Circ. Physiol. 293, H2210-H2218. doi: 10.1152/ajpheart.00688.2007
94. Rajesh, M., Pan, H., Mukhopadhyay, P., Bátkai, S., Osei-Hyiaman, D., Haskó, G., et al. (2007b). Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis. J. Leukoc. Biol. 82, 1382-1389. doi: 10.1189/jlb.0307180
95. Razdan, R. K., Dalzell, H. C., and Handrick, G. R. (1974). Hashis. a simple one-step synthesis of (-)-delta1-tetrahydrocannabinol (THC) from p-mentha-2, 8-dien-1-ol and olivetol. J. Am. Chem. Soc. 96, 5860-5865. doi: 10.1021/ja00825a026
96. Regal, K. M., Mercer, S. L., and Deweese, J. E. (2014). HU-331 is a catalytic inhibitor of topoisomerase II a. Chem. Res. Toxicol. 27, 2044-2051. doi: 10.1021/tx500245m
97. Reggio, P. H., Bramblett, R. D., Yuknavich, H., Seltzman, H. H., Fleming, D. N., Fernando, S. R., et al. (1995). The design, synthesis and testing of desoxy-CBD: further evidence for a region of steric interference at the cannabinoid receptor. Life Sci. 56, 2025-2032. doi: 10.1016/0024-3205(95)00185-9
98. Renard, J., Norris, C., Rushlow, W., and Laviolette, S. R. (2017). Neuronal and molecular effects of cannabidiol on the mesolimbic dopamine system: implications for novel schizophrenia treatments. Neurosci. Biobehav. Rev. 75, 157-165. doi: 10.1016/j.neubiorev.2017.02.006
99. Ribeiro, A., Almeida, V. I., Costola-de-Souza, C., Ferraz-de-Paula, V., Pinheiro, M. L., Vitoretti, L. B., et al. (2015). Cannabidiol improves lung function and inflammation in mice submitted to LPS-induced acute lung injury. Immunopharmacol. Immunotoxicol. 37, 35-41. doi: 10.3109/08923973.2014.976794
100. Robert, J. J., Ch, L., Ludwig Bercht, C. A., van Ooyen, R., and Spronck, H. J. W. (1977). Cannabinodiol: conclusive identification and synthesis of a new cannabinoid from Cannabis sativa. Phytochemistry 16, 595-597. doi: 10.1016/0031-9422(77)80023-X
101. Rock, E. M., Bolognini, D., Limebeer, C. L., Cascio, M. G., Anavi-Goffer, S., Fletcher, P. J., et al. (2012). Cannabidiol, a nonpsychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT 1A somatodendritic autoreceptors in the dorsal raphe nucleus. Br. J. Pharmacol. 165, 2620-2634. doi: 10.1111/j.1476-5381.2011.01621.x
102. Romero-Zerbo, S. Y., Rafacho, A., Díaz-Arteaga, A., Suárez, J., Quesada, I., Imbernon, M., et al. (2011). Role for the putative cannabinoid receptor GPR55 in the islets of Langerhans. J. Endocrinol. 211, 177-185. doi: 10.1530/JOE-11-0166
103. Rosenthaler, S., Pöhn, B., Kolmanz, C., Nguyen Huu, C., Krewenka, C., Huber, A., et al. (2014). Differences in receptor binding affinity of several phytocannabinoids do not explain their effects on neural cell cultures. Neurotoxicol. Teratol. 46, 49-56. doi: 10.1016/j.ntt.2014.09.003
104. Ruhaak, L. R., Felth, J., Karlsson, P. C., Rafter, J. J., Verpoorte, R., and Bohlin, L. (2011). Evaluation of the cyclooxygenase inhibiting effects of six major cannabinoids isolated from Cannabis sativa. Biol. Pharm. Bull. 34, 774-778. doi: 10.1248/bpb.34.774
105. Ruiz-Valdepeñas, L., Martínez-Orgado, J. A., Benito, C., Millán, A., Tolón, R. M., and Romero, J. (2011). Cannabidiol reduces lipopolysaccharide-induced vascular changes and inflammation in the mouse brain: an intravital microscopy study. J. Neuroinflammation 8:5. doi: 10.1186/1742-2094-8-5
106. Russo, E. B., Burnett, A., Hall, B., and Parker, K. K. (2005). Agonistic properties of cannabidiol at 5-HT1α receptors. Neurochem. Res. 30, 1037-1043. doi: 10.1007/s11064-005-6978-1
107. Ryberg, E., Larsson, N., Sjögren, S., Hjorth, S., Hermansson, N.-O., Leonova, J., et al. (2007). The orphan receptor GPR55 is a novel cannabinoid receptor. Br. J. Pharmacol. 152, 1092-1101. doi: 10.1038/sj.bjp.0707460
108. Schier, A., Ribeiro, N., Coutinho, D., Machado, S., Arias-Carrion, O., Crippa, J., et al. (2014). Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis sativa. CNS Neurol. Disord.-Drug Targets 13, 953-960. doi: 10.2174/1871527313666140612114838
109. Scuderi, C., Steardo, L., and Esposito, G. (2014). Cannabidiol promotes amyloid precursor protein ubiquitination and reduction of beta amyloid expression in SHSY5YAPP+ cells through PPARg involvement. Phyther. Res. 28, 1007-1013. doi: 10.1002/ptr.5095
110. Seephonkai, P., Popescu, R., Zehl, M., Krupitza, G., Urban, E., and Kopp, B. (2011). Ferruginenes A-C from rhododendron ferrugineum and their cytotoxic evaluation. J. Nat. Prod. 74, 712-717. doi: 10.1021/np100778k
111. Shani, A., and Mechoulam, R. (1974). Cannabielsoic acids: isolation and synthesis by a novel oxidative cyclization. Tetrahedron 30, 2437-2446. doi: 10.1016/S0040-4020(01)97114-5
112. Smoum, R., Baraghithy, S., Chourasia, M., Breuer, A., Mussai, N., Attar-Namdar, M., et al. (2015). CB2 cannabinoid receptor agonist enantiomers HU-433 and HU-308: an inverse relationship between binding affinity and biological potency. Proc. Natl. Acad. Sci. U.S.A. 112, 8774-8779. doi: 10.1073/pnas.1503395112
113. Stinchcomb, A. L., Golinski, M. J., Hammell, D. C., Howard, J. L., and Banks, S. L. (2009). Prodrugs of cannabidiol, compositions comprising prodrugs of cannabidiol, and methods of using the same. Patent No US2009036523A1. Washington, DC
114. Sumariwalla, P. F., Gallily, R., Tchilibon, S., Fride, E., and Mechoulam, R. (2004). A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis. Arthitis Rheum 50, 985-998. doi: 10.1002/art.20050
115. Taglialatela-Scafati, O., Pagani, A., Scala, F., De Petrocellis, L., Di Marzo, V., Grassi, G., et al. (2010). Cannabimovone, a cannabinoid with a rearranged terpenoid skeleton from hemp. Eur. J. Org. Chem 2067-2072. doi: 10.1002/ejoc.200901464
116. Takeda, S., Hirayama, A., Urata, S., Mano, N., and Aramaki, H. (2011). Cannabidiol-2', 6'-dimethyl ether as an effective protector of 15-lipoxygenase-mediated low-density lipoprotein oxidation in vitro. Biol. Pharm. Bull. 34, 1252-1256. doi: 10.1016/j.drudis.2011.09.009
117. Takeda, S., Hirota, R., Teradaira, S., and Takeda-imoto, M. (2015). Cannabidiol-2', 6'-dimethyl ether stimulates body weight gain in apolipoprotein E-deficient BALB/c, KOR/Stm. J. Toxicol. Sci. 40, 739-743. doi: 10.2131/jts.40.739
118. Takeda, S., Misawa, K., Yamamoto, I., and Watanabe, K. (2008). Cannabidiolic acid as a selective cyclooxygenase-2 inhibitory component in cannabis. Drug Metab. Dispos. 36, 1917-1921. doi: 10.1124/dmd.108.020909
119. Takeda, S., Okajima, S., Miyoshi, H., Yoshida, K., Okamoto, Y., Okada, T., et al. (2012). Cannabidiolic acid, a major cannabinoid in fiber-type cannabis, is an inhibitor of MDA-MB-231 breast cancer cell migration. Toxicol. Lett. 214, 314-319. doi: 10.1016/j.toxlet.2012.08.029
120. Takeda, S., Usami, N., Yamamoto, I., and Watanabe, K. (2009). Cannabidiol-2', 6'-dimethyl ether, a cannabidiol derivative, is a highly potent and selective 15-lipoxygenase inhibitor. Drug Metab. Dispos. 37, 1733-1737. doi: 10.1124/dmd.109.026930
121. Tanaka, H., Ichino, K., and Ito, K. (1984). A novel dihydrochalcone, linderatin from Lidera Umbellata Var, Lancea. Chem. Pharm. Bull. (Tokyo) 32, 3747-3750. doi: 10.1248/cpb.32.3747
122. Tchilibon, S., and Mechoulam, R. (2000). Synthesis of a primary metabolite of cannabidiol. Org. Lett. 2, 3301-3303. doi: 10.1021/ol006369a
123. Thomas, A., Baillie, G. L., Phillips, A. M., Razdan, R. K., Ross, R. A., and Pertwee, R. G. (2007). Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br. J. Pharmacol. 150, 613-623. doi: 10.1038/sj.bjp.0707133
124. Ujváry, I., and Hanuš, L. (2016). Human metabolites of cannabidiol: a review on their formation, biological activity, and relevance in therapy. Cannabis Cannabinoid Res. 1, 90-101. doi: 10.1089/can.2015.0012
125. Usami, N., Okuda, T., Yoshida, H., Kimura, T., Watanabe, K., Yoshimura, H., et al. (1999). Synthesis and pharmacological evaluation in mice of halogenated cannabidiol derivatives. Chem. Pharm. Bull. 47, 1641-1645. doi: 10.1248/cpb.47.1641
126. Vuolo, F., Petronilho, F., Sonai, B., Ritter, C., Hallak, J. E. C., Zuardi, A. W., et al. (2015). Evaluation of serum cytokines levels and the role of cannabidiol treatment in animal model of asthma. Mediators Inflamm. 2015:538670. doi: 10.1155/2015/538670
127. Watt, G., and Karl, T. (2017). In vivo evidence for therapeutic properties of cannabidiol (CBD) for alzheimer's disease. Front. Pharmacol. 8:20. doi: 10.3389/fphar.2017.00020
128. Whyte, L. S., Ryberg, E., Sims, N. A., Ridge, S. A., Mackie, K., Greasley, P. J., et al. (2009). The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc. Natl. Acad. Sci. U.S.A. 106, 16511-16516. doi: 10.1073/pnas.0902743106
129. Wright, S., Sommerville, K., Jones, N. A., and Whalley, B. J. (2015). Progress report on new antiepileptic drugs: a summary of the twelfth eilat conference (EILAT XII). Epilepsy Res. 111, 111-113. doi: 10.1016/j.eplepsyres.2015.01.001
130. Xiong, W., Cui, T., Cheng, K., Yang, F., Chen, S. R., Willenbring, D., et al. (2012). Cannabinoids suppress inflammatory and neuropathic pain by targeting alpha3 glycine receptors. J. Exp. Med. 209, 1121-1134. doi: 10.1084/jem.20120242
131. Yamamoto, I., Gohda, H., Narimatsu, S., Watanabe, K., and Yoshimura, H. (1991). Cannabielsoin as a new metabolite of cannabidiol in mammals. Pharmacol. Biochem. Behav. 40, 541-546. doi: 10.1016/0091-3057(91)90360-E
132. Yamaori, S., Okushima, Y., Masuda, K., Kushihara, M., Katsu, T., Narimatsu, S., et al. (2013). Structural requirements for potent direct inhibition of human cytochrome P450 1A1 by cannabidiol: role of pentylresorcinol moiety. Biol. Pharm. Bull. 36, 1197-1203. doi: 10.1248/bpb.b13-00183
133. Yang, K.-H., Galadari, S., Isaev, D., Petroianu, G., Shippenberg, T. S., and Oz, M. (2010). The nonpsychoactive cannabinoid cannabidiol inhibits 5-hydroxytryptamine3A receptor-mediated currents in Xenopus laevis oocytes. J. Pharmacol. Exp. Ther. 333, 547-554. doi: 10.1124/jpet.109.162594
134. Yin, H., Chu, A., Li, W., Wang, B., Shelton, F., Otero, F., et al. (2009). Lipid G protein-coupled receptor ligand identification using beta-arrestin Path Hunter assay. J. Biol. Chem. 284, 12328-12338. doi: 10.1074/jbc. M806516200
135. Zhornitsky, S., and Potvin, S. (2012). Cannabidiol in humans-the quest for therapeutic targets. Pharmaceuticals 5, 529-552. doi: 10.3390/ph5050529